← Leaderboards
Jennifer S Yu
Cleveland Clinic Lerner Com-Cwru
$6,177,422
Attributed
$7,581,012
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,581,012 · 6
By mechanism
R01$7,469,796 · 5
U54$111,216 · 1
Top collaborators
- Jianjun Zhao4 shared
- Liangqi Xie1 shared
Most similar at Cleveland Clinic Lerner Com-Cwru
Same institution · by research overlap
- Shideng Bao$9,894,339
- Anita Borton Hjelmeland$6,940,856
- Jeongwu Lee$5,183,445
- Tyler Eugene Miller$823,129
- Ryan Christopher Gimple$189,104
Others in their field
Top investigators on “Regulation”
- Kiyoshi Suyehiro · Iodp Management International, Inc$166,539,344
- David Heimbrook · Leidos Biomedical Research, Inc.$152,164,826
- Ralph Parchment · Leidos Biomedical Research, Inc.$141,315,269
- Nevan J Krogan · University Of California, San Francisco$101,337,442
- Asimah Rafi · Technical Resources Inc$95,881,052
- Richard C Boucher · University Of North Carolina Chapel Hill$83,460,414
Research focus
RegulationTumorGlioblastomaOverexpressionTherapeutic TargetTumor ProgressionPrimary Brain NeoplasmsSelf-RenewalResistanceMouse ModelSignal TransductionPathway InteractionsBindingRadiationGliomaAnimalsTumor GrowthStem CellsGenesProgramsCellsProteinsComplexReceptor
Grant awards (19)
Role of SMARCA5 in Glioblastoma$638,697
R01 · FY2025 · NS · contact PI
lncRNA regulation of glioblastoma progression and therapeutic resistance$547,221
R01 · FY2025 · NS · contact PI
Sema3C Signaling as an Alternative Activator of Canonical Wnt Signaling in Glioblastoma$402,500
R01 · FY2025 · NS · contact PI
Cross Training Core$111,216
U54 · FY2025 · CA · contact PI
lncRNA regulation of glioblastoma progression and therapeutic resistance$530,805
R01 · FY2024 · NS · contact PI
Sema3C Signaling as an Alternative Activator of Canonical Wnt Signaling in Glioblastoma$390,425
R01 · FY2024 · NS · contact PI
lncRNA regulation of glioblastoma progression and therapeutic resistance$547,221
R01 · FY2023 · NS · contact PI
Sema3C Signaling as an Alternative Activator of Canonical Wnt Signaling in Glioblastoma$402,500
R01 · FY2023 · NS · contact PI
lncRNA regulation of glioblastoma progression and therapeutic resistance$543,237
R01 · FY2022 · NS · contact PI
Selective Targeting of Glioma Stem Cells Through Sema3C/PlexinD1$346,719
R01 · FY2020 · NS · contact PI
Selective Targeting of Glioma Stem Cells Through Sema3C/PlexinD1$346,719
R01 · FY2019 · NS · contact PI
Hypoxia Regulates Notch Turnover in Glioma Stem Cells Through Vasorin$346,719
R01 · FY2019 · NS · contact PI
Hypoxia Regulates Notch Turnover in Glioma Stem Cells Through Vasorin$346,719
R01 · FY2018 · NS · contact PI
Selective Targeting of Glioma Stem Cells Through Sema3C/PlexinD1$346,719
R01 · FY2018 · NS · contact PI
Hypoxia Regulates Notch Turnover in Glioma Stem Cells Through Vasorin$346,719
R01 · FY2017 · NS · contact PI
Selective Targeting of Glioma Stem Cells Through Sema3C/PlexinD1$346,719
R01 · FY2017 · NS · contact PI
Hypoxia Regulates Notch Turnover in Glioma Stem Cells Through Vasorin$346,719
R01 · FY2016 · NS · contact PI
Selective Targeting of Glioma Stem Cells Through Sema3C/PlexinD1$346,719
R01 · FY2016 · NS · contact PI
Hypoxia Regulates Notch Turnover in Glioma Stem Cells Through Vasorin$346,719
R01 · FY2015 · NS · contact PI